Tuberculosis incidence in patients treated with secukinumab – a real-world study in Brazil
Felipe Merchan Ferraz Grizzo, Sineida Maria Berbert Ferreira, Maria Victória Suárez Restrepo, Anber Ancel Tanaka, André Vicente Esteves de Carvalho, Roberto Ranza, Felipe Thies, Juliana Cabrera Garrido · 2025
Read Tuberculosis incidence in patients treated with secukinumab – a real-world study in Brazil by Felipe Merchan Ferraz Grizzo, Sineida Maria Berbert Ferreira, Maria Victória Suárez Restrepo, Anber Ancel Tanaka, André Vicente Esteves de Carvalho, Roberto Ranza, Felipe Thies, Juliana Cabrera Garrido (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13488818.txt.
Description
Felipe Merchan Ferraz Grizzo and co-authors published this 2025 real-world study on tuberculosis risk in Brazilians taking secukinumab. The drug blocks interleukin-17 to treat psoriasis and related joint diseases. Older biologics that block a different signal are known to raise tuberculosis risk, but data for this newer class were scarce, a gap that matters in a country where tuberculosis remains common.
Charts covered 152 adults treated for at least two years, followed for about forty months on average. Most had psoriatic arthritis, and the group averaged fifty-two years of age. The study counts new tuberculosis cases across that long exposure window. Such real-world tallies help doctors weigh screening and monitoring for patients on the drug.
Catalog record
| CREATOR | Felipe Merchan Ferraz Grizzo, Sineida Maria Berbert Ferreira, Maria Victória Suárez Restrepo, Anber Ancel Tanaka, André Vicente Esteves de Carvalho, Roberto Ranza, Felipe Thies, Juliana Cabrera Garrido |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |